Biotech Values

[DewDiligence]

GRTS enrolls first patient in phase-1 neoantigen trial:

https://www.globenewswire.com/news-release/2019/03/21/1758939/0/en/Gritstone-Oncology-Announces-First-Patient-Dosed-in-a-Clinical-Study-Evaluating-its-Personalized-Immunotherapy-GRANITE-001.html

Gritstone Oncology…today announced that the first patient has been dosed with its personalized immunotherapy candidate targeting the patient’s tumor-specific neoantigens, called GRANITE-001.

The Phase 1/2 clinical study, referred to as GO-004, is evaluating GRANITE-001 in combination with immune checkpoint blockade for the treatment of patients with advanced solid tumors, including microsatellite stable colorectal cancer (MSS CRC), gastroesophageal cancer, metastatic non-small cell lung cancer, and bladder cancer.